Abstract Library

#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers

Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,

#2789 The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET)

Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Holgersson K

Authors: Holgersson K, Ståhl E, Nilsson M, Grauers B, Mårtensson-Djäken E,

Keywords: SINET, patients' experience, interview,

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours

Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sorbye H

Authors: Sorbye H, Meyer L, Mordal K, Myhre S, Thiis-Evensen E,

Keywords: Quality of life, small-intestinal neuroendocrine tumors, patient reported symptoms, coping, somatostatin analogue,